239 related articles for article (PubMed ID: 33407744)
1. Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences.
Priedigkeit N; Ding K; Horne W; Kolls JK; Du T; Lucas PC; Blohmer JU; Denkert C; Machleidt A; Ingold-Heppner B; Oesterreich S; Lee AV
Breast Cancer Res; 2021 Jan; 23(1):1. PubMed ID: 33407744
[TBL] [Abstract][Full Text] [Related]
2. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
3. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
Hartmaier RJ; Trabucco SE; Priedigkeit N; Chung JH; Parachoniak CA; Vanden Borre P; Morley S; Rosenzweig M; Gay LM; Goldberg ME; Suh J; Ali SM; Ross J; Leyland-Jones B; Young B; Williams C; Park B; Tsai M; Haley B; Peguero J; Callahan RD; Sachelarie I; Cho J; Atkinson JM; Bahreini A; Nagle AM; Puhalla SL; Watters RJ; Erdogan-Yildirim Z; Cao L; Oesterreich S; Mathew A; Lucas PC; Davidson NE; Brufsky AM; Frampton GM; Stephens PJ; Chmielecki J; Lee AV
Ann Oncol; 2018 Apr; 29(4):872-880. PubMed ID: 29360925
[TBL] [Abstract][Full Text] [Related]
4. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
[TBL] [Abstract][Full Text] [Related]
6. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
7. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.
Fumagalli D; Wilson TR; Salgado R; Lu X; Yu J; O'Brien C; Walter K; Huw LY; Criscitiello C; Laios I; Jose V; Brown DN; Rothé F; Maetens M; Zardavas D; Savas P; Larsimont D; Piccart-Gebhart MJ; Michiels S; Lackner MR; Sotiriou C; Loi S
Ann Oncol; 2016 Oct; 27(10):1860-6. PubMed ID: 27672107
[TBL] [Abstract][Full Text] [Related]
9. Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors.
Muthukaruppan A; Lasham A; Woad KJ; Black MA; Blenkiron C; Miller LD; Harris G; McCarthy N; Findlay MP; Shelling AN; Print CG
Clin Breast Cancer; 2017 Apr; 17(2):139-153. PubMed ID: 27756582
[TBL] [Abstract][Full Text] [Related]
10. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
11. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
12. Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
Robinson DR; Wu YM; Vats P; Su F; Lonigro RJ; Cao X; Kalyana-Sundaram S; Wang R; Ning Y; Hodges L; Gursky A; Siddiqui J; Tomlins SA; Roychowdhury S; Pienta KJ; Kim SY; Roberts JS; Rae JM; Van Poznak CH; Hayes DF; Chugh R; Kunju LP; Talpaz M; Schott AF; Chinnaiyan AM
Nat Genet; 2013 Dec; 45(12):1446-51. PubMed ID: 24185510
[TBL] [Abstract][Full Text] [Related]
13. Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer.
Xia Y; He X; Renshaw L; Martinez-Perez C; Kay C; Gray M; Meehan J; Parker JS; Perou CM; Carey LA; Dixon JM; Turnbull A
Clin Cancer Res; 2022 Aug; 28(16):3618-3629. PubMed ID: 35653148
[TBL] [Abstract][Full Text] [Related]
14. Concordance of genomic alterations between primary and recurrent breast cancer.
Meric-Bernstam F; Frampton GM; Ferrer-Lozano J; Yelensky R; Pérez-Fidalgo JA; Wang Y; Palmer GA; Ross JS; Miller VA; Su X; Eroles P; Barrera JA; Burgues O; Lluch AM; Zheng X; Sahin A; Stephens PJ; Mills GB; Cronin MT; Gonzalez-Angulo AM
Mol Cancer Ther; 2014 May; 13(5):1382-9. PubMed ID: 24608573
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
16. Integrative molecular profiling identifies a novel cluster of estrogen receptor-positive breast cancer in very young women.
Park C; Yoon KA; Kim J; Park IH; Park SJ; Kim MK; Jang W; Cho SY; Park B; Kong SY; Lee ES
Cancer Sci; 2019 May; 110(5):1760-1770. PubMed ID: 30811755
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
18. ER
Guerrero-Zotano AL; Stricker TP; Formisano L; Hutchinson KE; Stover DG; Lee KM; Schwarz LJ; Giltnane JM; Estrada MV; Jansen VM; Servetto A; Gavilá J; Perez-Fidalgo JA; Lluch A; Llombart-Cussac A; Bayar MA; Michiels S; André F; Arnedos M; Guillem V; Ruiz-Simon A; Arteaga CL
Clin Cancer Res; 2018 Jun; 24(11):2517-2529. PubMed ID: 29581135
[No Abstract] [Full Text] [Related]
19. Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.
Padró M; Louie RJ; Lananna BV; Krieg AJ; Timmerman LA; Chan DA
BMC Cancer; 2017 Mar; 17(1):203. PubMed ID: 28320353
[TBL] [Abstract][Full Text] [Related]
20. PSF Promotes ER-Positive Breast Cancer Progression via Posttranscriptional Regulation of
Mitobe Y; Iino K; Takayama KI; Ikeda K; Suzuki T; Aogi K; Kawabata H; Suzuki Y; Horie-Inoue K; Inoue S
Cancer Res; 2020 Jun; 80(11):2230-2242. PubMed ID: 32213542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
